The effect of proprotein convertase subtilisin kexin type 9 inhibitors on the survival of patients at extreme cardiovascular risk in real clinical practice

Abstract

BACKGROUND: Among non-communicable diseases, cardiovascular diseases occupy a leading position in terms of mortality rate in developed countries, including Russia. In the clinical practice of the Russian Federation, almost all modern methods and means of treating patients with cardiovascular diseases are used. In particular, innovative lipid-lowering drugs are used, such as proprotein convertase inhibitors subtilisin/kexin type 9 — alirocumab and evolocumab. However, at the moment there is no complete information on how these drugs affect the survival of patients at extreme cardiovascular risk, both worldwide and in Russia. In this regard, the study of this issue is an important and urgent task.

AIM: To evaluate the efficacy and safety of proprotein convertase inhibitors subtilisin / kexin type 9 in patients at extreme cardiovascular risk. Also, to assess the effect of these drugs on the survival of patients of this category of cardiovascular risk.

MATERIAL AND METHODS: The study involved 104 patients at extreme cardiovascular risk. The patients were divided into two groups: the main group (53 people) and the control group (51 people). In the control group, the patients received standard lipid-lowering therapy: statin at the maximum tolerated dosage and/or ezetimibe, and in the main group, standard lipid-lowering therapy was supplemented with drugs of proprotein convertase inhibitors subtilisin/kexin type 9.

The results of laboratory research methods were analyzed in dynamics, and the frequency of side effects was evaluated. All cases of cardiovascular events, including mortality, were recorded. Based on the data obtained, we analyzed the survival rate and frequency of major cardiovascular events.

RESULTS: In the main group, month after starting therapy with proprotein convertase inhibitors subtilisin/kexin type 9, the level of low-density lipoproteins in all the patients decreased by more than 50% from the initial value. The target level of low-density lipoproteins was reached by 42 out of 53 observed patients. These results remained stable until the end of the study. No cases of hepatotoxicity, myopathy, or other local side effects were reported during the period of use of proprotein convertase inhibitors subtilisin/kexin type 9. In the control group, the lipidogram of patients did not change significantly during the study. In addition, there were more cases of recurrent cardiovascular events, including mortality, in the patients in the control group.

CONCLUSIONS: In real clinical practice, proprotein convertase inhibitors subtilisin / kexin type 9 has demonstrated high efficacy and safety in patients at extreme cardiovascular risk. Thanks to the use of these drugs, it was possible to achieve the target levels of low-density lipoproteins and increase patient’s adherence to treatment. As a result, the prognosis for patients with an extreme risk of cardiovascular complications improved.

Keywords

proprotein convertase subtilisin kexin type 9 inhibitors / PCSK9 inhibitors / extreme cardiovascular risk / survival

References

[1] Sharapova OV, Kicha DI, Gerasimova LI, et al. Map analysis of morbidity and mortality from blood circulatory system diseases of the population of the Russian federation (2010-2019). Complex Issues of Cardiovascular Diseases. 2022;11(1):56–68. EDN: ZUQVNA doi: 10.17802/2306-1278-2022-11-1-56-68

[2] Шарапова О.В., Кича Д.И., Герасимова Л.И., и др. Картографический анализ показателей заболеваемости и смертности от болезней системы кровообращения населения Российской Федерации (2010-2019 гг.) // Комплексные проблемы сердечно-сосудистых заболеваний. 2022. Т. 11, № 1. С. 56–68. EDN: ZUQVNA doi: 10.17802/2306-1278-2022-11-1-56-68

[3] Ezhov MV, Kukharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250–297. EDN: YVZOWJ doi: 10.15829/1560-4071-2023-5471

[4] Ежов М.В., Кухарчук В.В., Сергиенко И.В., и др. Нарушения липидного обмена. Клинические рекомендации 2023 // Российский кардиологический журнал. 2023. Т. 28, № 5. С. 250–297. EDN: YVZOWJ doi: 10.15829/1560-4071-2023-5471

[5] Barbarash OL, Karpov YuA, Kashtalap VV, et al. 2020 clinical practice guidelines for stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):201–250. EDN: THCMQS doi: 10.15829/1560-4071-2020-4076

[6] Барбараш О.Л., Карпов Ю.А., Кашталап В.В., и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020 // Российский кардиологический журнал. 2020. Т. 25, № 11. С. 201–250. EDN: THCMQS doi: 10.15829/1560-4071-2020-4076

[7] Drapkina OM, Imaeva AE, Kutsenko VA, et al. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(S8):92–104. EDN: DGYJLA doi: 10.15829/1728-8800-2023-3791

[8] Драпкина О.М., Имаева А.Э., Куценко В.А., и др. Дислипидемии в Российской Федерации: популяционные данные, ассоциации с факторами риска // Кардиоваскулярная терапия и профилактика. 2023. Т. 22, № S8. C. 92–104. EDN: DGYJLA doi: 10.15829/1728-8800-2023-3791

[9] Drapkina OM, Shalnova SA, Imaeva AE, et al. Epidemiology of cardiovascular diseases in regions of Russian Federation. Third survey (ESSE-RF-3). Rationale and study design. Cardiovascular Therapy and Prevention. 2022;21(5):48–57. EDN: EZUGUW doi: 10.15829/1728-8800-2022-3246

[10] Драпкина О.М., Шальнова С.А., Имаева А.Э., и др. Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации. Третье исследование (ЭССЕ-РФ-3). Обоснование и дизайн исследования // Кардиоваскулярная терапия и профилактика. 2022. T. 21, № 5. С. 48–57. EDN: EZUGUW doi: 10.15829/1728-8800-2022-3246

[11] Boytsov SA, Drapkina OM, Shlyakhto EV, et al. Epidemiology of cardiovascular diseases and their risk factors in regions of Russian Federation (ESSE-RF) study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):143–152. EDN: ZPGROP doi: 10.15829/1728-8800-2021-3007

[12] Бойцов С.А., Драпкина О.М., Шляхто Е.В., и др. Исследование ЭССЕ-РФ (Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя // Кардиоваскулярная терапия и профилактика. 2021. Т. 20, № 5. С. 143–152. EDN: ZPGROP doi: 10.15829/1728-8800-2021-3007

[13] Visseren FLJ, Mach F, Smulderst YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Russian Journal of Cardiology. 2022;27(7):191–288. EDN: VQDNIK doi: 10.15829/1560-4071-2022-5155

[14] Visseren F.L.J., Mach F., Smulderst Y.M., и др. 2021 Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике // Российский кардиологический журнал. 2022. Т. 27, № 7. С. 191–288. EDN: VQDNIK doi: 10.15829/1560-4071-2022-5155

[15] Lokhmacheva AV, Fominykh SG, Trubina LV, Sikhvardt IE. Assessment of the global and national market for lipid modifying agents: retrospective and innovation. Journal of Siberian Medical Sciences. 2023;43(4):23–43. EDN: JIQUMC doi: 10.18699/SSMJ20230403

[16] Лохмачева А.В., Фоминых С.Г., Трубина Л.В., Сихвардт И.Э. Оценка мирового и национального рынка гиполипидемических средств: ретроспектива и инновации // Сибирский научный медицинский журнал. 2023. Т. 43, № 4. С. 23–43. EDN: JIQUMC doi: 10.18699/SSMJ20230403

[17] Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397. doi: 10.1056/NEJMoa1410489

[18] Cannon C.P., Blazing M.A., Giugliano R.P., et al. Ezetimibe added to statin therapy after acute coronary syndromes // N Engl J Med. 2015. Vol. 372, N 25. P. 2387–2397. doi: 10.1056/NEJMoa1410489

[19] Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008;52(25):2198–2205. doi: 10.1016/j.jacc.2008.10.031

[20] Fleg J.L., Mete M., Howard B.V., et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) trial // J Am Coll Cardiol. 2008. Vol. 52, N 25. P. 2198–2205. doi: 10.1016/j.jacc.2008.10.031

[21] Rozhkov DE, Tyrenko VV, Nikitin AE. The problem of achieving the target concentrations of low-density lipoproteins cholesterol in real clinical practice: the data of the survey of doctors of different specialties. Therapy. 2021;7(6):62–71. EDN: QOEQDA doi: 10.18565/therapy.2021.6.62-71

[22] Рожков Д.Е., Тыренко В.В., Никитин А.Э. Проблема достижения целевых концентраций холестерина липопротеидов низкой плотности в реальной клинической практике: данные анкетирования врачей различных специальностей // Терапия. 2021. Т. 7, № 6. С. 62–71. EDN: QOEQDA doi: 10.18565/therapy.2021.6.62-71

[23] Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962–1971. doi: 10.1016/S0140-6736(17)32290-0

[24] Giugliano R.P., Pedersen T.R., Park J.G., et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial // Lancet. 2017. Vol. 390, N 10106. P. 1962–1971. doi: 10.1016/S0140-6736(17)32290-0

[25] Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: A prespecified analysis from the FOURIER Trial. JAMA Cardiol. 2019;4(7):613–619. doi: 10.1001/jamacardio.2019.0886

[26] Murphy S.A., Pedersen T.R., Gaciong Z.A., et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: A prespecified analysis from the FOURIER trial // JAMA Cardiol. 2019. Vol. 4, N 7. P. 613–619. doi: 10.1001/jamacardio.2019.0886

[27] Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2022;43(7):e17–e25. doi: 10.1093/eurheartj/ehz430

[28] Guedeney P., Giustino G., Sorrentino S., et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials // Eur Heart J. 2022. Vol. 43, N 7. P. 17–e25. doi: 10.1093/eurheartj/ehz430

[29] Nikitin AE, Averin EE, Rozhkov DE, et al. Alirocumab administration experience to achieve low density lipoprotein cholesterol target levels in secondary prevention of cardiovascular disease. Rational Pharmacotherapy in Cardiology. 2020;16(1):33–39. EDN: FIXDSY doi: 10.20996/1819-6446-2020-02-06

[30] Никитин А.Э., Аверин Е.Е., Рожков Д.Е., и др. Опыт применения алирокумаба для достижения целевых уровней холестерина липопротеинов низкой плотности у пациентов, нуждающихся во вторичной профилактике сердечно-сосудистых заболеваний // Рациональная фармакотерапия в кардиологии. 2020. Т. 16, № 1. С. 33–39. EDN: FIXDSY doi: 10.20996/1819-6446-2020-02-06

[31] Zimerman A, O’Donoghue ML, Ran X, et al. Long-term neurocognitive safety of LDL-C lowering with evolocumab: open-label extension data from FOURIER. Circulation. 2023;148(Suppl_1):A14714. doi: 10.1161/circ.148.suppl_1.14714

[32] Zimerman A., O’Donoghue M.L., Ran X., et al. Long-term neurocognitive safety of LDL-C lowering with evolocumab: open-label extension data from FOURIER // Circulation. 2023. Vol. 148, N Suppl_1. Р. A14714. doi: 10.1161/circ.148.suppl_1.14714

[33] Gencer B, Mach F, Guo J, et al. Cognition after lowering LDL-cholesterol with evolocumab. J Am Coll Cardiol. 2020;75(18):2283–2293. doi: 10.1016/j.jacc.2020.03.039

[34] Gencer B., Mach F., Guo J., et al. Cognition after lowering LDL-cholesterol with evolocumab // J Am Coll Cardiol. 2020. Vol. 75, N 18. P. 2283–2293. doi: 10.1016/j.jacc.2020.03.039

[35] Martsevich SYu, Afonina OS, Zagrebelnyy AV, et al. Comparative assessment of long-term survival of patients after primary and recurrent myocardial infarction: a data from the RIMIS registry. Cardiovascular Therapy and Prevention. 2024;23(5):25–33. EDN: NVMOXY doi: 10.15829/1728-8800-2024-4001

[36] Марцевич С.Ю., Афонина О.С., Загребельный А.В., и др. Сравнительная оценка отдаленной выживаемости пациентов, перенесших первичный и повторный инфаркт миокарда. Данные регистра РИМИС // Кардиоваскулярная терапия и профилактика. 2024. T. 23, № 5. С. 25–33. EDN: NVMOXY doi: 10.15829/1728-8800-2024-4001

[37] Karpov YA. The Role of PCSK9 inhibitors in the improvement of outcomes in patients after acute coronary syndrome: Results of ODYSSEY OUTCOMES trial. Rational Pharmacotherapy in Cardiology. 2018;14(6):922–934. EDN: VTJAMW doi: 10.20996/1819-6446-2018-14-6-922-934

[38] Карпов Ю.А. Ингибиторы PCSK9 в улучшении прогноза у пациентов после острого коронарного синдрома: данные исследования ODYSSEY OUTCOMES // Рациональная фармакотерапия в кардиологии. 2018. Т. 14, № 6. С. 922–934. EDN: VTJAMW doi: 10.20996/1819-6446-2018-14-6-922-934

[39] Sinnaeve PR, Schwartz GG, Wojdyla DM, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020;41(24):2248–2258. doi: 10.1093/eurheartj/ehz809

[40] Sinnaeve P.R., Schwartz G.G., Wojdyla D.M., et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis // Eur Heart J. 2020. Vol. 41, N 24. P. 2248–2258. doi: 10.1093/eurheartj/ehz809

RIGHTS & PERMISSIONS

Eco-Vector